ASYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES IN POSTMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that most commonly occurs in women. Improved treatments for SLE have led to a substantial increase in the life expectancy of patients, so the problems of complications of both the disease itself and its therapy have come to be top priority. The most common complications of SLE among the musculoskeletal system lesions are osteoporosis and related vertebral compression fractures (VCFs). However, only one third of these fractures has clinical manifestations and causes the patient to seek medical advice. More VCFs remain undetected because they have no or scarce symptoms. The question of the influence of various factors (gender, age, menopause, etc.) on the incidence of VCFs in patients with SLE remains open. It should be expected that in postmenopausal women with SLE, the incidence of VCFs may be considerably higher than that in the population.

Objective: to determine the frequency of and to evaluate the role of various factors in the development of asymptomatic vertebral fractures in postmenopausal women with SLE (a retrospective study).

Subjects and methods. A total of 86 postmenopausal women (mean age, 59±7.9 years) with a diagnosis of SLE, which met the 2012 Systemic Lupus Collaborating Clinics (SLICC) criteria, were examined. The mean duration of the disease and menopause was 15±8.3 and 12.8±7 years, respectively. All the patients with SLE were treated with glucocorticoids (GC) at a dose of 15±5 mg/day calculated with reference to prednisolone for more than 12 months (mean, 159.7±90.9 months) and had a low disease activity (the mean SLEDAI-2K score was 5.1±3.9). The ACR damage index for SLE averaged 5.5±2.6. All the patients underwent vertebral fracture assessment (VFA) using a Hologic Explorer bone densitometer to identify VCFs in the thoracic and lumbar spine. The anterior, middle, and posterior heights of ТhIV–LV, and the height of each vertebra as well as the underlying vertebra were calculated and compared. If the differences in the anterior, middle, or posterior vertebral heights were >20–25%, this deformation was regarded as VCFs. Bone mineral density (BMD) in the hip and spine was measured with an X-ray bone densitometer.

Results. VFA revealed VCFs in 40 (46.5%) patients with SLE; these were detected for the first time in 22 (55%) patients since they had no significant clinical manifestations. VCFs happened most commonly in the mid-thoracic spine (ThVI–IX). All the patients with asymptomatic VCFs had a fracture of only one vertebra. The patients with VCFs had a longer duration of SLE and menopause, more frequently received cytostatic therapy, and had a higher cumulative dose and a longer duration of GC therapy. They also had a higher damage index and lower BMD values in LI–IV than patients without VCFs (p < 0.05). Neither SLE activity nor hip BMD was associated with VCFs (p > 0.05).

Conclusion. The detection rate for VCFs is nearly 50% in postmenopausal women with SLE, and about every two VCFs remain undetected. The long duration of SLE, menopause, and GC treatment, a high cumulative dose, a high damage index and low BMD values in LI–IV were associated with VCFs. VFA is an effective screening method to detect asymptomatic VCFs.

1. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum. 1993;36:1726-34. doi: 10.1002/art.1780361212

2. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14:106-12. doi: 10.1191/0961203305lu2039oa

3. Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheum. 2003;22:318-23. doi: 10.1007/s10067-003-0743-0

4. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone. 2006;39:253-9. doi: 10.1016/j.bone.2006.02.005

5. Almehed K, Hetenyi S, Ohlsson C, et al. Prevalence and risk factors of vertebral compression fractures in female SLE patients. Arthritis Res Ther. 2010;12:R153. doi: 10.1186/ar3104

6. Rentero ML, Amigo E, Chozas N, et al. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. BMC Musculoskelet Disord. 2015;16:300. doi: 10.1186/s12891-015-0733-9

7. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi: 10.1002/art.34473

8. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40. doi: 10.1002/art.1780350606

9. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809-13. doi: 10.1002/art.1780400506

10. Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809-16. doi: 10.1007/s00198-010-1524-7

11. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. Bone Miner Res. 1996;11:984-96. doi: 10.1002/jbmr.5650110716

12. Михайлов ЕЕ, Беневоленская ЛИ, Баркова ТВ. Эпидемиологическая характеристика переломов конечностей в популяционной выборке лиц 50 лет и старше. Остеопороз и остеопатии. 1998;(2):2-6 [Mikhailov EE, Benevolenskaya LI, Barkova TV. Epidemiological characteristics of vertebral fractures in a population sample of individuals 50 years and older. Osteoporoz i Osteopatii. 1998;(2):2-6 (In Russ.)].

13. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167:1-34.

14. Закроева АГ, Андриянова ОВ, Солодовников АГ. Сравнительное исследование показателей психического здоровья и их ассоциаций с факторами риска хронических неинфекционных заболеваний в сельской и городской популяциях. Уральский медицинский журнал. 2009;2(56):83-93 [Zakroeva AG, Andriyanova OV, Solodovnikov AG. A comparative study of indicators of mental health and its association with risk factors for chronic noncommunicable diseases in rural and urban populations. Ural’skii Meditsinskii Zhurnal. 2009;2(56):83-93 (In Russ.)].

15. Лесняк ОМ, Баранова ИА, Торопцова НВ. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Ярославль; 2013. 48 с. [Lesnyak OM, Baranova IA, Toroptsova NV. Klinicheskie rekomendatsii «Diagnostika, profilaktika i lechenie glyukokortikoidnogo osteoporoza u muzhchin i zhenshchin 18 let i starshe» [Clinical guidelines "Diagnosis, prevention and treatment of glucocorticoid osteoporosis in men and women 18 years and older"]. Yaroslavl'; 2013. 48 p.].

16. Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004;15:20-6. doi: 10.1007/s00198-003-1463-7

17. Евстигнеева ЛП. Эпидемиологическое исследование остеопоротических деформаций позвонков у жителей г. Екатеринбурга старших возрастных групп: Дисс. … канд. мед. наук. Ярославль; 2002 [Evstigneeva LP. Epidemiologicheskoe issledovanie osteoporoticheskikh deformatsii pozvonkov u zhitelei g. Ekaterinburga starshikh vozrastnykh grupp: Diss. … kand. med. nauk [An epidemiological study of osteoporotic vertebral deformities among residents of the city of Yekaterinburg in older age groups: Diss. ... Cand. Med. Sci.]. Yaroslavl'; 2002].

18. Соловьев СК, Асеева ЕА, Попкова ТВ и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9-16 [Soloviev SK, Aseeva EA, Popkova TV, et al. Treat-to-target SLE recommendations from the international task force and russian experts’ commentaries. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):9-16 (In Russ.)]. doi: 10.14412/1995-4484-2015-9-16

19. Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheum. 2009;28:579-85. doi: 10.1007/s10067-009-1105-3

20. Samelson EJ, Hannan MT, Zhang Y, et al. Incidence and risk factors for vertebral fracture in women and men: 25 year follow-up results from the population-based Framingham study. Bone Miner Res. 2006;21:1207-14. doi: 10.1359/jbmr.060513